FDA (Drugs) recall action 69519
The FDA (Drugs) publishes a recall like this one as 56 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 56 pages.
Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.
Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection
Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection..
The agency’s own wording, quoted from the enforcement report.
The unit total adds up the quantities the agency stated for each product. Where a product record gave no figure, or gave a weight rather than a count, it contributes nothing — so the real total is at least this, never less.
Oregon Compounding Centers is recalling Gentamicin Sulfate irrigation solution due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Ganciclovir syringes due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Papaverine/Phentolamine/Prostaglandin injectable vials due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling injectable Methycobalamin vials due to quality control issues that present a potential risk to sterility assurance.
Oregon Compounding Centers is recalling Ceftazidime syringes because quality control issues observed during an FDA inspection may compromise sterility assurance.
Oregon Compounding Centers is recalling Vitamin B Complex injectable vials due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling Copper Sulfate injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling specific lots of injectable Papaverine HCL/Phentolamine/Prostaglandin due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling Mitomycin injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Renacidin solution due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling AVASTIN syringes because quality control issues observed during an FDA inspection present a potential risk to sterility assurance.
Oregon Compounding Centers is recalling Mitomycin injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Procaine HCL injectable vials due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling Epinephrine 1:1000 injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling DMPS injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Tobramycin solution for irrigation due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling injectable ascorbic acid vials because quality control issues observed during an FDA inspection present a potential risk to sterility assurance.
Oregon Compounding Centers is recalling Bevacizumab/Dexamethasone injectable syringes due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling injectable glutathione vials because quality control issues observed during an FDA inspection present a potential risk to sterility assurance.
Oregon Compounding Centers is recalling specific lots of Methycobalamin injectable due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Dexpantenol injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Alprostadil/Lidocaine HCL vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling Alprostadil injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
Oregon Compounding Centers is recalling injectable Methylcobalamin due to quality control issues affecting sterility assurance.
Oregon Compounding Centers is recalling 145 vials of Chorionic Gonadotropin due to quality control issues affecting sterility assurance.